Vancouver, Canada – September 8, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced it will exhibit and present new data at the Congress of Clinical Rheumatology West (CCR West) 2025, taking place September 18–21 in Huntington Beach, California. CCR West is a premier forum where rheumatologists, researchers, and industry leaders gather to share advances in rheumatic disease diagnostics, treatments, and patient care.
The new research highlights the diagnostic utility of 14-3-3eta protein in rheumatoid arthritis (RA) and 14-3-3eta autoantibodies in axial spondyloarthritis (axSpA). In RA, the findings reinforce the diagnostic value of serum 14-3-3eta, showing significantly elevated levels in RA patients compared to a broad spectrum of disease controls. In axSpA, the data demonstrate that 14-3-3eta autoantibodies are complementary to CRP and HLA-B27, with utility to improve diagnostic accuracy and support timely treatment decisions.
Poster Presentations:
High Specificity and Diagnostic Utility of Serum 14-3-3η in Rheumatoid Arthritis: Evidence from a Clinically Diverse Cohort
Validation of a 14-3-3η Autoantibody Assay Combined with CRP and HLA-B27 to Improve Axial Spondyloarthritis (axSpA) Detection
- Presenting Author: Dr. Anthony Marotta, PhD
- Date and Time: Friday, September 19 at 3:10 PM
In addition to the poster presentations, Augurex will showcase its innovations at Booth 48. Attendees can connect with the team to learn more about Augurex’s biomarker-driven solutions, including JOINTstat® | 14-3-3eta, a diagnostic and monitoring biomarker for RA, and SPINEstat® | Anti-14-3-3eta Multiplex, a first-in-class diagnostic test for the detection of axSpA. Together, these solutions are designed to shorten the time to diagnosis, support treatment decisions, and improve patient outcomes.
To learn more about CCR West 2025 or to connect with the Augurex team during the conference, visit:
Congress of Clinical Rheumatology – West 2025
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com